Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Melanotan I / Afamelanotide.

Research draft

Afamelanotide is a melanocortin analogue; Melanotan I is a related market label requiring formulation checks.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Identity and evidence review notes

Confirm exact identity, sequence, alias or formulation before attaching product-specific evidence.

Overview

Afamelanotide is a melanocortin analogue; Melanotan I is a related market label requiring formulation checks.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It activates pigmentation-related melanocortin signalling.

Human research

Clinical evidence for the regulated implant concerns erythropoietic protoporphyria. It does not validate injectable tanning products.

Preclinical & other research

Pigmentation studies provide biological rationale, not general skin-protection guarantees.

Safety & unknowns

Pigmented-lesion monitoring and product-specific adverse effects matter.

Regulatory status

US Scenesse is an approved implant for a defined indication. Implant evidence cannot be transferred to unregulated injections.

Reported use & evidence

Research profile draft

The supplied Melanotan I / Afamelanotide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Follow the cited records and registered research. Profiles remain research drafts.

Explore more compounds